EIF2AK2 and melanoma: Indeed, PKR has been identified as overexpressed and activated in several cancers including hematopoietic malignancies (Basu et al., 1997), breast cancer (Kim et al., 2000), melanoma, and colon cancer (Kim et al., 2002).